138 related articles for article (PubMed ID: 11837547)
1. Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections.
Li JZ; Willke RJ; Rittenhouse BE; Glick HA
Pharmacotherapy; 2002 Feb; 22(2 Pt 2):45S-54S. PubMed ID: 11837547
[TBL] [Abstract][Full Text] [Related]
2. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
[TBL] [Abstract][Full Text] [Related]
3. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial.
Li Z; Willke RJ; Pinto LA; Rittenhouse BE; Rybak MJ; Pleil AM; Crouch CW; Hafkin B; Glick HA
Pharmacotherapy; 2001 Mar; 21(3):263-74. PubMed ID: 11256381
[TBL] [Abstract][Full Text] [Related]
4. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis.
Willke RJ; Glick HA; Li JZ; Rittenhouse BE
Int J Technol Assess Health Care; 2002; 18(3):540-54. PubMed ID: 12391947
[TBL] [Abstract][Full Text] [Related]
5. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M; Sorensen SV; Liu LZ
Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
[TBL] [Abstract][Full Text] [Related]
6. Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections.
Parodi S; Rhew DC; Goetz MB
J Manag Care Pharm; 2003; 9(4):317-26. PubMed ID: 14613450
[TBL] [Abstract][Full Text] [Related]
7. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species.
McCollum M; Rhew DC; Parodi S
Clin Ther; 2003 Dec; 25(12):3173-89. PubMed ID: 14749155
[TBL] [Abstract][Full Text] [Related]
9. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
[TBL] [Abstract][Full Text] [Related]
10. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
11. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
Weigelt J; Itani K; Stevens D; Lau W; Dryden M; Knirsch C;
Antimicrob Agents Chemother; 2005 Jun; 49(6):2260-6. PubMed ID: 15917519
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
[TBL] [Abstract][Full Text] [Related]
13. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
Nathwani D
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
[TBL] [Abstract][Full Text] [Related]
14. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE; Erstad BL; Nix DE
Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
[TBL] [Abstract][Full Text] [Related]
17. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Daniel Mullins C; Kuznik A; Shaya FT; Obeidat NA; Levine AR; Liu LZ; Wong W
Clin Ther; 2006 Aug; 28(8):1184-1198. PubMed ID: 16982296
[TBL] [Abstract][Full Text] [Related]
19. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]